On August 14, 2023, Shanghai Escugen Biotechnology Co., Ltd. ("Escugen") and Shanghai ChemExpress Co., Ltd. ("ChemExpress") reached a strategic cooperation agreement.

On June 4, 2023, Escugen's ESG401 (Trop2 ADC) made a notable appearance at the 2023 ASCO meeting, presenting preliminary data from its first-in-human study in the form of a poster.